ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The holding company Innoviva will purchase La Jolla Pharmaceutical for about $149 million. The deal includes two US Food and Drug Administration–approved products: the vasoconstrictor Giapreza and the antibacterial Xerava, both of which are FDA approved. Innoviva has also completed the acquisition of Entasis Therapeutics, which specializes in developing treatments for multidrug-resistant, gram-negative bacteria. Innoviva says its long-term strategy is to amass a portfolio of drugs for infectious disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter